- Home
- RYTM vs PTGX Comparison
RYTM vs PTGX Comparison
Compare RYTM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYTM | PTGX |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.4B |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RYTM | PTGX |
|---|---|---|
| Price | $111.98 | $85.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $127.31 | $90.56 |
| AVG Volume (30 Days) | 966.4K | ★ 1.1M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | $174,334,000.00 | ★ $209,217,000.00 |
| Revenue This Year | $47.34 | N/A |
| Revenue Next Year | $57.18 | $296.47 |
| P/E Ratio | ★ N/A | $119.12 |
| Revenue Growth | ★ 54.92 | N/A |
| 52 Week Low | $45.91 | $33.70 |
| 52 Week High | $122.20 | $96.54 |
Technical Indicators
Market Signals| Indicator | RYTM | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 57.05 | 47.49 |
| Support Level | $109.99 | $84.11 |
| Resistance Level | $115.05 | $96.54 |
| Average True Range (ATR) | 5.20 | 3.32 |
| MACD | 0.60 | -0.87 |
| Stochastic Oscillator | 53.93 | 18.55 |
Price Performance
Historical ComparisonAbout RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.